[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hcm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hcm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100655750","phase-3-clinical-trial-of-a-mek-inhibitor-for-rasopathy-associated-severe-infantile-hypertrophic-cardiomyopathy-baby-merit-100655750",false,"NCT07817186","Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT","Baby MERIT","Inclusion Criteria:\n\n* Molecular genetic diagnosis of a RASopathy signaling through the RAS\u002FMAPK pathway as identified by molecular assays performed in a Clinical Laboratory Improvements of 1988 (CLIA) or similarly certified laboratories. Qualifying genotypes will included variants in any gene causing Noonan, Costello or cardiofaciocutaneous syndrome curated as pathogenic or likely pathogenic and consistent with the genetic mechanism (i.e., one allele in genes acting in an autosomal dominant manner and two alleles in trans for the autosomal recessive form of LZTR1-related Noonan syndrome).\n* Diagnosis of HCM, as defined by LV and interventricular septal wall thickness with a z-score \\> 2 by echocardiography\n* Age ≥ 28 days and ≤ 6 months\n* Ross classification of HF of III or IV\n* Hospitalization\n* In the opinion of the site investigator, ability to comply with study protocol requirements\n* Signed informed consent for the trial by a parent or legal guardian\n\nExclusion Criteria:\n\n* PTPN11 pathogenic\u002Flikely pathogenic variants causing NSML\n* Prior treatment with a MEK inhibitor\n* Requiring treatment with strong inhibitors of CYP2C19 and CYP3A4, strong inducers of CYP3A4, and substrates of CYP2C9 with a narrow therapeutic index\n* Platelet count \\\u003C 50,000\u002FµL\n* Neoplastic disorder requiring treatment (e.g., juvenile myelomonocytic leukemia)","ALL","28 Days","6 Months",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This project seeks to perform a Phase 3 clinical trial to test whether an FDA-approved cancer drug called trametinib is effective in treating young infants with genetic conditions called RASopathies and a severe, life-threatening heart problem called hypertrophic cardiomyopathy. The purpose of this research is to demonstrate that trametinib is effective in preventing these sick babies from dying, receiving a heart transplant or undergoing heart surgery to remove extra heart muscle over a one-year period. In addition, the investigators will determine how often this heart problem comes back when the trametinib treatment is stopped.",[27,28,29],"HCM","Noonan Syndrome and Other Rasopathy","Heart Failure (Pediatric)",[31,32,33,34,35,36],"Noonan Syndrome","RAS-HCM","RASopathy","Heart failure","trametinib","MEK inhibitor","NOT_YET_RECRUITING","2026-09-08",{"date":40,"type":41},"2026-09-14","ACTUAL",{"date":43,"type":21},"2027-08-01",{"date":45,"type":21},"2032-06-30",{"name":47,"class":48},"Carelon Research","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100630088","valsalva-sbp-drop-and-lvot-obstruction-100630088","NCT07483125","Valsalva SBP Drop and LVOT Obstruction","Safety and Efficacy of Non-invasive and Ambulatory Hemodynamic Monitoring for Evaluating the Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy","Inclusion Criteria:1: ① Age ≥ 18 years\n\n2: ② Diagnosed with hypertrophic cardiomyopathy (HCM) by echocardiography, with or without left ventricular outflow tract obstruction\n\n3: ③ Conscious and mentally competent, able to understand and voluntarily sign the informed consent form\n\n4: ④ Able to cooperate with the completion of provocation tests, non-invasive dynamic hemodynamic monitoring, and relevant follow-up examinations.\n\n\\-\n\nExclusion Criteria:\n\n* 1: ① Age ≤ 18 years, or pregnant\u002Flactating patients\n\n  2: ② Presence of other organic heart or great vessel diseases that cause left ventricular outflow tract obstruction, such as severe aortic stenosis, congenital subaortic membrane, etc.\n\n  3: ③ Complicated with persistent atrial fibrillation or other severe arrhythmias that may affect the accuracy of hemodynamic monitoring\n\n  4: ④ Previous history of interventional or surgical therapy for left ventricular outflow tract obstruction, including septal ablation or myectomy\n\n  5: ⑤ Patients with other conditions considered inappropriate by the investigators (e.g., those with absolute or relative contraindications to provocation tests)\n\n  6: ⑥ Patients currently participating in other clinical studies.","18 Years",{"count":58,"type":21},800,"1 Year","OBSERVATIONAL","This study aimed to evaluate the efficacy of non-invasive dynamic blood pressure monitoring in assessing left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. We prospectively collected SBP waveforms and LVOT gradient data from patients with obstructive and non-obstructive disease, systematically analyzed their correlation, and explored its clinical value in different clinical scenarios.",[27,63,64],"oHCM","nHCM","RECRUITING","2026-03-15",{"date":68,"type":41},"2026-03-19",{"date":70,"type":41},"2025-12-01",{"date":72,"type":21},"2026-12-31",{"name":74,"class":48},"Shanghai Zhongshan Hospital",1]